GeneralInformation
Immunogen
Vlm tumor cells
Fusion Species
Mouse X Mouse Hybridoma
Immunological Donor
BALB/c mice splenocytes
Cell Line Description
Established in 1982 by immunizing BALB/c mice with VLM tumor cells and fusing splenocytes with SP2/0-Ag14 myeloma cells; described as secreting a mouse monoclonal antibody (igg2akappa) detecting epitopes of wild type p53 (not mutant or denatured p53), that occur on human, primate, bovine, mouse and rat cells, by ELISA and immunoblotting confirmed as mouse with IEF of LDH, NP.
Cytogenetics: murine flat-moded hypertetraploid karyotype 82-97<4n> several centric fusion markers present.
Viruses: ELISA: reverse transcriptase positive
Morphology
single round cells growing in suspension, partly slightly adherent
Growth Properties
suspension, partly slightly adherent
CultureMethod
Subculturing
Split ratio: 1: 2 to 1: 3, every second day; seed out at 0.5 x 10^6 cells/ml; Maintain at 0.3-0.4 x 10^6 cells/ml; Maximal density at 0.7 x 10^6 cells/ml; Doubling time: 24 hours; Harvest: 0.5 x 10^6 cells/ml.
Some cells attach to the flask surface, but may be detached by tapping the flask; if viability decreases, addition of HFCS ( Hybridoma Fusion and Cloning Supplement ) may be useful.
Storage
Liquid nitrogen vapor phase.
Freezing medium: to complete growth medium(20%FBS), add 10%(v/v) DMSO
Target
Synonyms
Antigen NY-CO-13; Cellular tumor antigen p53; Cys 51 Stop; FLJ92943; HGNC11998; LFS1; p53; p53 Cellular Tumor Antigen; p53 tumor suppressor; P53_HUMAN; Phosphoprotein p53; Tp53; Transformation related protein 53; TRP53; Tumor protein p53; Tumor suppressor p53; Tumour Protein p53;
Citations
Have you cited CSC-H1465 in a publication?
Let us know and earn a reward for your research.
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
Valgardsdottir, R; Tryggvadottir, L; et al. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS 105:121-130(1997).
Payne, AS; Yan, AC; et al. Two novel TP63 mutations associated with the ankyloblepharon, ectodermal defects, and cleft lip and palate syndrome - A skin fragility phenotype. ARCHIVES OF DERMATOLOGY 141:1567-1573(2005).
COA
Certificate of Analysis
 Antibody_1.gif)
